Download PDF
Thromb Haemost 2004; 92(01): 67-74
DOI: 10.1160/TH04-02-0107
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease

Kristien M. M. Ver Elst
1   Department of Haematology, Erasmus Medical Center, Rotterdam,The Netherlands
,
Huub D. M. van Vliet
1   Department of Haematology, Erasmus Medical Center, Rotterdam,The Netherlands
,
Mies C. Kappers-Klunne
1   Department of Haematology, Erasmus Medical Center, Rotterdam,The Netherlands
,
Frank W. G. Leebeek
1   Department of Haematology, Erasmus Medical Center, Rotterdam,The Netherlands
› Author AffiliationsFinancial support: This study was financially supported by Baxter.
Further Information

Publication History

Received 19 February 2004

Accepted after resubmission 20 April 2004

Publication Date:
29 November 2017 (online)

    Permissions and Reprints

Summary

Patients with type 2 and 3 von Willebrand disease (VWD) are treated with factor VIII/VWF concentrate in case of bleeding or surgery. Immunate® (Baxter, Vienna, Austria) is a double virus inactivated FVIII/VWF concentrate and is registered in several countries for patients with VWD with reduced FVIII levels.We performed an in vitro, a pharmacokinetic and a clinical study to evaluate Immunate in VWD. In vitro studies showed a significant variation in VWF levels in 9 different batches. The median (range) values (in IU/mL) were 1.10 (0.98-1.30) for FVIII:C, 1.34 (0.95-1.61) for VWF:Ag, 0.60 (0.27-1.08) for VWF:CBA and 0.73 (0.59-0.94) for VWF:RCo. The relatively low VWF activity is mainly due to the lack of high molecular weight multimers (HMWM), as determined by electrophoresis. A pharmacokinetic study showed, based on a content of FVIII:C of 1 U/mL, in vivo recoveries (%) of 106 (56-150) (median and range) for FVIII:C, 105 (62-187) for VWF:Ag, 25 (7-41) for VWF:CBA and 43 (11-76) for VWF:RCo. Half-lives were 14.1 h (7.4-36.9) for FVIII:C, 10.8 h (7.7-26.2) for VWF:Ag, 15.3 h (7.8-44.6) for VWF:CBA and 16.4 h (4.2-26.5) for VWF:RCo. In a clinical study efficacy was determined after infusion given before surgery or dental extractions in ten patients. In two patients the hemostatic response was classified as inadequate. In conclusion, there is a wide variability in VWF concentration and activity in various batches of Immunate®. In the clinical study in which the dosage was based on FVIII:C contents of the concentrate, two out of ten patients had an insufficient haemostatic response. Therefore dosing of Immunate dosing should not be based on FVIII:C levels, but should be based on VWF activity of the individual batches. Future studies using a VWF activity-guided dosage regimen have to be performed to establish the efficacy of Immunate in the treatment of von Willebrand disease.

Keywords

von Willebrand disease - factor VIII/VWF concentrate - bleeding - pharmacokinetics
 

  • References

  • 1 Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Mannucci PM. Treatment of von Willebrand disease. Thromb Haemost 2001; 86: 149-53.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Federichi AB, Mannucci PM. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Haemophilia 1998; 04 (Suppl. 03) 7-10.
    CrossrefPubMedGoogle Scholar
  • 4 Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand’s disease type III. Ann Hematol 1992; 65: 253-9.
    CrossrefPubMedGoogle Scholar
  • 5 Mannucci PM, Tenconi PM, Castaman G. et al. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: cross-over randomised trial. Blood 1992; 79: 3130-7.
    PubMedGoogle Scholar
  • 6 Federici AB, Baudo F, Caracciolo C. et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002; 08 (06) 761-7.
    CrossrefPubMedGoogle Scholar
  • 7 Sixma JJ, Eikenboom HCJ. Behandeling van de ziekte van von Willebrand. Consensus hemofilie: behandeling en verantwoordelijkheid 1996; 178: 566-70.
    PubMedGoogle Scholar
  • 8 Agrawal YP, Dzik W. The VWF content of factor VIII concentrates. Transfusion 2001; 41: 153-4.
    CrossrefPubMedGoogle Scholar
  • 9 Slaby JA, Pruthi RK, Wilke JL. et al. Von Willebrand factor (vWF) concentrates: vWF multimer patterns, factor VIII and vWF content, and therapeutic efficacy. Haemophilia. 2000 06. 253 Abstract.
    PubMedGoogle Scholar
  • 10 Sluiter T, Budde U, Metzner HJ. et al. Comparison of von Willebrand factor activities measured by ristocetin cofactor assay and two different VWF-collagen-binding-assays in VWF/FVIII-concentrates. J Thromb Haemost. 2003 01. suppl. 1667 (abstract).
    PubMedGoogle Scholar
  • 11 Chang P, Aronson DL. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost 1997; 78: 930-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Auerswald G, Eberspacher B, Engl W. et al. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate®). Semin Thromb Hemost 2002; 28: 203-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Brosstad F, Kjonniksen I, Ronnig B. et al. Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost 1986; 55: 276-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Lee ML, Poon W-Y, Kingdon HS. A twophase linear regression model for biologic half-life data. J Lab Clin Med 1990; 115: 745-8.
    PubMedGoogle Scholar
  • 15 Björkman S, Carlsson M, Berntorp E. et al. Pharmacokinetics of factor VIII in humans – Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 1992; 22: 385-95.
    CrossrefPubMedGoogle Scholar
  • 16 Rodeghiero F, Castaman G, Meyer D. et al. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992; 62: 193-9.
    PubMedGoogle Scholar
  • 17 Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 04: 33-9.
    PubMedGoogle Scholar
  • 18 Mannucci PM, Chediak J, Hanna W. et al. band the Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate; a prospective, multicenter study. Blood 2002; 99 (02) 450-6.
    CrossrefPubMedGoogle Scholar
  • 19 Lubetsky A, Martinowitz U, Luboshitz J. et al. Efficacy and safety of factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. Haemophilia 2002; 08 (05) 622-8.
    CrossrefPubMedGoogle Scholar
  • 20 Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Assay of human von Willebrand factor. PharmEuropa 2002; 14.2: 377-8.
    PubMedGoogle Scholar
  • 22 Neugebauer BM, Goy C, Seitz R. A collagen binding assay: an additional method for von Willebrand factor activity in therapeutic concentrates. Thromb Haemost 2002; 88: 871-2.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Fischer BE, Kramer G, Mitterer A. et al. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res 1996; 84 (01) 55-66.
    CrossrefPubMedGoogle Scholar
  • 24 Hanna WT, Bona RD, Zimmerman CE. et al. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand diseases. Thromb Haemost 1994; 71: 173-9.
    PubMedGoogle Scholar
  • 25 Lubetsky A, Schulman S, Varon D. et al. Safety and efficacy of continuous infusion of combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost 1999; 81: 229-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Lillicrap D, Poon MC, Walker I. et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P:ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-30.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Turecek PL, Schonhofer W, Kreil TR. et al. Immunate S/D A new Factor VIII- von Willebrand complex concentrate. 33rd Hemophilia Symposium Hamburg. 2002. Eds. Scharrer I, Schramm W. 117-34.
    Google Scholar
  • 28 Committee for proprietary medicinal products; ad hoc working party on biotechnology/pharmacy and working party on safety medicines. EEC regulatory document, note for guidance, validation of virus removal and inactivation procedures. Biologicals 1991; 19: 247-51.
    CrossrefPubMedGoogle Scholar
  • 29 Hubbard AR, Sands D, Chang AC. et al. Standardization of von Willebrand factor in therapeutic concentrates: calibration of the 1st international standard for von Willebrand factor concentrate (00/514). Thromb Haemost 2002; 88: 380-6.
    Article in Thieme ConnectPubMedGoogle Scholar